Pirtobrutinib (JAYPIRCA)
Criteria for Use
October 2024

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the *PBM INTRAnet* site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive pirtobrutinib.

- ☐ Patient has not been screened for Hepatitis B Virus (HBV)
- ☐ Unmanageable drug-drug or drug-food interaction identified
- ☐ Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (NYHA Class 3 or 4), or myocardial infarction in prior 6 months
- ☐ Current or history of central nervous system (CNS) lymphoma
- ☐ Active or uncontrolled infection
- ☐ Pregnancy
- ☐ Lactating

Inclusion Criteria

One of the following criteria must be met.

- ☐ Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor
- ☐ Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor

Additional Inclusion Criteria: Select if applicable

- ☐ For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 1 week after stopping treatment
- ☐ Advise patients not to breastfeed and/or provide breastmilk to an infant during treatment and for at least 1 weeks after the last dose

Additional Inclusion Criteria

All of the following criteria must be met:

- ☐ Eastern Cooperative Oncology Group Performance Status 0-2
- ☐ Care provided by a VA/VA Community Care hematology/oncology provider
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented

---

Prepared: October 2024. Brooke Wallace. Contact: Bernadette B. Heron PharmD, BCOP, National PBM Clinical Pharmacy Program Manager, Formulary management, VA Pharmacy Benefits Management Services (12PBM)